Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Profound Medical Corp. - common stock (NQ:PROF)

6.140 +0.110 (+1.82%)
Delayed Quote Updated: 2:19 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Profound Medical Corp. - common stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound’s Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days’
Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Announces Management Change
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical (PROF) Q2 2026 Earnings Call Transcript ↗
Record orders and expanding payer coverage mark commercial inflection. 
Via The Motley Fool
Topics Earnings
News headline image
Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey
A patient-centered initiative focused on education, connection, and support 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Q2 Earnings Call Highlights ↗
Profound Medical (NASDAQ:PROF) reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from CAD 2.2 million a year earlier, as the company said the reported figure was affected by the timing of... 
Via MarketBeat
Topics Earnings
News headline image
Profound Medical Reports Second Quarter 2026 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial
– Whole-gland TULSA ablation demonstrates statistically significant superior penile length preservation compared to robotic RP at 1 month – 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
Company to explore the potential of integrating TULSA-PRO with PSMA PET molecular imaging technologies to enhance ablation planning and monitoring 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Q1 Earnings Call Highlights ↗
Profound Medical (NASDAQ:PROF) reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use,... 
Via MarketBeat
Topics Earnings
News headline image
Profound Medical Reports Strong First Quarter 2026 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
From Pomerantz LLP
Via GlobeNewswire
News headline image
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
From Profound Medical Corp.
Via GlobeNewswire
News headline image
CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
From Profound Medical Corp.
Via GlobeNewswire
Here are the top movers in Friday's session. ↗
Via Chartmill
News headline image
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
From Profound Medical Corp.
Via GlobeNewswire
News headline image
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditions 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Announces Upcoming Investor Events
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systems 
From Profound Medical Corp.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.